Background & relevance

  • Optimal management of muscle-invasive bladder cancer (MIBC) goes beyond performing radical cystectomy (RC) and requires the involvement of a multidisciplinary team.
  • Neoadjuvant and adjuvant cisplatin-containing combination chemotherapy has been used since the 1980s but has limitations, including patient selection and response rate. Novel trials with immunotherapy in the neoadjuvant and adjuvant setting demonstrate promising results that may change the treatment landscape of MIBC.
  • In this module, all patients have urothelial carcinoma (UCa) in absence of (extensive) variant histology.

Regulatory approval status of drugs for MIBC (status 1 December 2021)

Back